MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

---

ZAMAGNİ E., Boccadoro M., Spencer A., DELFORGE M., Reece D., Einsele H., ...More

64th ASH Annual Meeting & Exposition, United States Of America, 9 - 12 December 2022, (Full Text)

• Publication Type: Conference Paper / Full Text
• Country: United States Of America
• Ankara University Affiliated: Yes